Comparing Different Ways of Giving Bimekizumab

This open-label clinical study is currently enrolling adults to evaluate how bimekizumab moves through the body (its pharmacokinetics) and whether it is safe when administered by different routes, such as by injection versus another method.

Duration

~ 6 months

Visits

6 – 8 clinic visits

Compensation

Yes, Provided

Location

Bellevue, WA

About This Trial

This open-label clinical study is currently enrolling adults to evaluate how bimekizumab moves through the body (its pharmacokinetics) and whether it is safe when administered by different routes, such as by injection versus another method.

Participants will receive bimekizumab using different methods of administration so researchers can compare how the medication is absorbed, distributed, and processed by the body. The goal is to determine whether these different delivery methods produce similar results and to help identify the most effective and convenient way to administer the medication in the future.

Condition: Various (pharmacokinetics study in adults)
Learn more: View on CenterWatch

Check Your Eligibility Screening

Answer a few questions to see if you may qualify for our gout clinical trial.

Eligibility screening is not available at the moment.

This is completely confidential, your answers are processed locally and are not stored or transmitted. Only your contact information is saved if you choose to submit it.

Other Trials

We have several clinical trials and you may be eligible for more than one. Lets find out.

Comparing Different Ways of Giving Bimekizumab

This open-label clinical study is currently enrolling adults to evaluate how bimekizumab moves through the body (its pharmacokinetics) and whether it is safe when administered by different routes, such as by injection versus another method.

About This Trial

Check Your Eligibility Screening

Other Trials

Evaluating Sarilumab for Adults with Early Polymyalgia Rheumatica (PMR)

Testing Natrunix Combined with Methotrexate for Rheumatoid Arthritis

Using a Molecular Test to Guide Treatment Choice for Rheumatoid Arthritis

Continued Secukinumab Treatment for Prior Novartis Study Participants

V Secukinumab Safety Study for Giant Cell Arteritis or Polymyalgia Rheumatica

Testing a New Combination Treatment for Gout

Testing a New Treatment (LY3871801) for Moderate-to-Severe Rheumatoid Arthritis

Blood Sample Study for Rheumatoid Arthritis Patients Starting a New Medication

AR882 for Gout Patients Who Have Not Responded to Prior Uricase Therapy

Testing LY2439821 for Moderate-to-Severe Plaque Psoriasis

Testing Nipocalimab for Moderate-to-Severe Sjögren’s Disease

Testing Afimetoran for Active Lupus (SLE)